Daratumumab monotherapy in patients with heavily pretreated ...

final results from the phase 2 GEN501 and SIRIUS trials - PubMed

Background: Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here ...

Clinical efficacy of daratumumab monotherapy in patients with ...

On the basis of these findings, the US Food and Drug Administration granted accelerated approval of daratumumab monotherapy (16 mg/kg) for the treatment of ...

Daratumumab monotherapy in patients with heavily pretreated ...

Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies.

Clinical efficacy of daratumumab monotherapy in patients ... - PubMed

The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported.

Daratumumab monotherapy in patients with heavily pretreated ...

Daratumumab 16 mg/kg monotherapy provides durable responses; no new safety concerns were identified with longer follow-up.

Daratumumab monotherapy in patients with treatment-refractory ...

Interpretation Daratumumab monotherapy showed encouraging effi cacy in heavily pretreated and refractory patients with multiple myeloma ...

Daratumumab Monotherapy in Heavily Pretreated Asian Patients ...

Results: The overall response rate was 42.1%, including one complete remission (4.8%) and three very good partial responses (14.3%). The cycles of daratumumab ...

final results from the phase 2 GEN501 and SIRIUS trials - The Lancet

Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies.

Paper: Clinical Efficacy of Daratumumab Monotherapy in Patients ...

29 Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma Clinically Relevant ...

Daratumumab monotherapy in patients with treatment-refractory ...

Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in ...

Daratumumab Monotherapy in Patients with Heavily Pretreated ...

In the combined analysis, the objective response rate (ORR) was 31%, and the rate of very good partial response or better was 13%, with 2 patients achieving ...

Safety and Efficacy of Daratumumab Monotherapy in Patients with ...

Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from ...

final results from the phase 2 GEN501 and SIRIUS trials

Background: Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here ...

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma.

Daratumumab monotherapy in patients with heavily pretreated ...

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. · S ...

Daratumumab Shows High Activity in Heavily Pretreated and ...

Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favorable ...

Daratumumab monotherapy compared with historical control data in ...

1 INTRODUCTION. Comparative assessments of new agents for the treatment of heavily pretreated patients with relapsed and refractory multiple ...

Daratumumab Monotherapy in Heavily Pretreated Asian Patients ...

Conclusion: Daratumumab monotherapy showed fairly promising activity with modest tolerance in heavily treated Asian RRMM patients. Multiple myeloma (MM) marks ...

Daratumumab monotherapy in patients with treatment-refractory ...

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.

final results from the phase 2 GEN501 and SIRIUS trials

Background Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple myeloma in the GEN501 and ...